Novel strategies for the pharmacological management of type 2 diabetes

被引:23
作者
Nourparvar, A
Bulotta, A
Di Mario, U
Perfetti, R
机构
[1] Cedars Sinai Med Ctr, Div Endocrinol & Metab, Los Angeles, CA 90048 USA
[2] Univ Roma La Sapienza, Dept Clin Sci, Rome, Italy
关键词
D O I
10.1016/j.tips.2003.12.007
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Type 2 diabetes is characterized by high concentrations of glucose in the blood, which is caused by decreased secretion of insulin from the pancreas and decreased insulin action. This condition is prevalent worldwide and is associated with morbidity and mortality secondary to complications such as myocardial infarction, stroke and end-stage renal disease. The importance of tight control of blood glucose in either preventing or delaying the progression of complications is recognized. Currently, there are many therapeutic options to treat hyperglycemia in type 2 diabetes. However, tight control is difficult to achieve and is often associated with side-effects. Recent advances in understanding insulin secretion, action and signaling have led to the development of new pharmacological agents. In this article, we review new molecules that are promising candidates for the future management of diabetes, focusing on their mechanism of action, efficacy, safety profile and potential benefits compared with pharmacological agents that are available currently.
引用
收藏
页码:86 / 91
页数:6
相关论文
共 60 条
[1]   The potential antidiabetic activity of some alpha-2 adrenoceptor antagonists [J].
Abdel-Zaher, AO ;
Ahmed, IT ;
El-Koussi, AEA .
PHARMACOLOGICAL RESEARCH, 2001, 44 (05) :397-409
[2]   Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes [J].
Ahrén, B ;
Simonsson, E ;
Larsson, H ;
Landin-Olsson, M ;
Torgeirsson, H ;
Jansson, PA ;
Sandqvist, M ;
Båvenholm, P ;
Efendic, S ;
Eriksson, JW ;
Dickinson, S ;
Holmes, D .
DIABETES CARE, 2002, 25 (05) :869-875
[3]  
*AM DIAB ASS, 2001, DIABETES CARE, V26, pS5
[4]   Threonine phosphorylations induced by RX-871024 and insulin secretagogues in βTC6-F7 cells [J].
An, J ;
Zhao, GS ;
Churgay, LM ;
Osborne, JJ ;
Hale, JE ;
Becker, GW ;
Gold, G ;
Stramm, LE ;
Shi, YG .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 1999, 277 (05) :E862-E869
[5]   Stimulation of insulin secretion in clonal BRIN-BD11 cells by the imidazoline derivatives KU14R and RX801080 [J].
Ball, AJ ;
Flatt, PR ;
McClenaghan, NH .
PHARMACOLOGICAL RESEARCH, 2000, 42 (06) :575-579
[6]   Insulinotropic action of novel succinic acid esters [J].
Bjorkling, F ;
MalaisseLagae, F ;
Malaisse, WJ .
PHARMACOLOGICAL RESEARCH, 1996, 33 (4-5) :273-275
[7]  
Bodvarsdottir TB, 2002, DIABETES, V51, pA359
[8]   4-Hydroxyisoleucine: experimental evidence of its insulinotropic and antidiabetic properties [J].
Broca, C ;
Gross, R ;
Petit, P ;
Sauvaire, Y ;
Manteghetti, M ;
Tournier, M ;
Masiello, P ;
Gomis, R ;
Ribes, G .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 1999, 277 (04) :E617-E623
[9]   4-Hydroxyisoleucine: effects of synthetic and natural analogues on insulin secretion [J].
Broca, C ;
Manteghetti, M ;
Gross, R ;
Baissac, Y ;
Jacob, M ;
Petit, P ;
Sauvaire, Y ;
Ribes, G .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 390 (03) :339-345
[10]   Interactions between insulin resistance and insulin secretion in the development of glucose intolerance [J].
Cavaghan, MK ;
Ehrmann, DA ;
Polonsky, KS .
JOURNAL OF CLINICAL INVESTIGATION, 2000, 106 (03) :329-333